The Goldman Sachs Group downgraded shares of Charles River Laboratories International (NYSE:CRL – Free Report) from a buy ...

Two UIC professors list their questions for the man set to lead "the crown jewel” of American biomedical science.

Research at a Duke University laboratory led to a new breast cancer drug in 2023. Government funding for that lab is now in ...

Government investment in research, hospitals and universities is what saved older cities after U.S. manufacturing imploded in ...

Five years ago, the Covid-19 pandemic swept through the world, resulting in massive disruptions, including to biomedical ...

As the world's demand for highly skilled medical professionals continues to grow, aspiring doctors seek institutions that ...

B-cell Acute Lymphoblastic Leukemia (B-ALL) is a life-threatening and highly aggressive form of blood cancer. It is the most common childhood cancer, making up 35% of pediatric cancer cases, but it ...

Motion sickness is a very common condition that affects about 1 in 3 people, but the brain circuits involved are largely unknown. In the current study published in Nature Metabolism, researchers at ...

Q4 2024 revenue of $1.5 million in pharma services; full year revenue of $1.9 millionGraftAssure RUO assay launched July ...

One canceled project at Vanderbilt University had been following the overall health of more than 1,200 LGBTQ people age 50 ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.

We recently published a list of the 12 Best Diagnostics Stocks to Invest In Right Now. In this article, we are going to take a look at where Charles River Laboratories International, Inc.